Portal Hypertension - Pipeline Review, H1 2016

  • ID: 3691117
  • Drug Pipelines
  • 73 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Gilead Sciences, Inc.
  • LinXis B.V.
  • Mezzion Pharma Co. Ltd.
  • MORE
Portal Hypertension - Pipeline Review, H1 2016

Summary

‘Portal Hypertension - Pipeline Review, H1 2016’, provides an overview of the Portal Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Portal Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Portal Hypertension and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Portal Hypertension
- The report reviews pipeline therapeutics for Portal Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Portal Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Portal Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Portal Hypertension

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Portal Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Portal Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Gilead Sciences, Inc.
  • LinXis B.V.
  • Mezzion Pharma Co. Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Portal Hypertension Overview

Therapeutics Development

Pipeline Products for Portal Hypertension - Overview

Portal Hypertension - Therapeutics under Development by Companies

Portal Hypertension - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Portal Hypertension - Products under Development by Companies

Portal Hypertension - Companies Involved in Therapeutics Development

Conatus Pharmaceuticals Inc.

Galectin Therapeutics, Inc.

Gilead Sciences, Inc.

Intercept Pharmaceuticals, Inc.

LinXis B.V.

Mezzion Pharma Co. Ltd.

Ono Pharmaceutical Co., Ltd.

Portal Hypertension - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

emricasan - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GRMD-02 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GS-9674 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LIN-003 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

obeticholic acid - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ONO-1266 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

udenafil - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Portal Hypertension - Recent Pipeline Updates

Portal Hypertension - Dormant Projects

Portal Hypertension - Discontinued Products

Portal Hypertension - Product Development Milestones

Featured News & Press Releases

Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting

Sep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis

Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting

Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting

Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension

Nov 08, 2012: Intercept Pharma To Present Phase IIa Portal Hypertension Data At AASLD's Annual Liver Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Portal Hypertension, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Portal Hypertension - Pipeline by Conatus Pharmaceuticals Inc., H1 2016

Portal Hypertension - Pipeline by Galectin Therapeutics, Inc., H1 2016

Portal Hypertension - Pipeline by Gilead Sciences, Inc., H1 2016

Portal Hypertension - Pipeline by Intercept Pharmaceuticals, Inc., H1 2016

Portal Hypertension - Pipeline by LinXis B.V., H1 2016

Portal Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H1 2016

Portal Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Portal Hypertension Therapeutics - Recent Pipeline Updates, H1 2016

Portal Hypertension - Dormant Projects, H1 2016

Portal Hypertension - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Portal Hypertension, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Conatus Pharmaceuticals Inc.
Galectin Therapeutics, Inc.
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
LinXis B.V.
Mezzion Pharma Co. Ltd.
Ono Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll